A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients With Advanced Malignant Tumors

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-04-0901
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The Insulin-Like Growth Factor-I Receptor Inhibitor Figitumumab (CP-751,871) in Combination With Docetaxel in Patients With Advanced Solid Tumours: Results of a Phase Ib Dose-Escalation, Open-Label Study

British Journal of Cancer
Cancer ResearchOncology
2010English

Phase I Study of the Pan-Pi3k Inhibitor Buparlisib in Adult Chinese Patients With Advanced Solid Tumors

Anticancer Research
MedicineCancer ResearchOncology
2016English

A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2006English

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2014English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies

Clinical Therapeutics
Pharmacology
2016English

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy